Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • snt951 snt951 Sep 24, 2013 7:40 AM Flag

    Combination of ganetespib (G) plus docetaxel (D) improves overall survival (OS)

    From their press release:

    Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced results from an interim survival analysis of the GALAXY-1 trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company’s lead drug candidate, the Hsp90 inhibitor ganetespib, as second-line treatment for patients with advanced non-small cell lung adenocarcinoma. The results show that the combination of ganetespib (G) plus docetaxel (D) improves overall survival (OS) and progression-free-survival (PFS) compared to docetaxel alone. The results also show that these improvements are enhanced in the pre-specified patient population that was selected last year for evaluation in the ongoing GALAXY-2 Phase 3 trial.

 
SNTA
1.98+0.12(+6.45%)Aug 27 4:00 PMEDT